TheraRadar
← Back
Data updated: Jun 28, 2026

BIOCON GENERICS

Generics
Cardiovascular Execution: Excellent

BIOCON GENERICS is a generic drug manufacturer focused on Cardiovascular.

2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

BIOCON GENERICS at a Glance

  • Strong track record with 82% execution quality across 9 trials
  • Fast trial execution (7 months median completion)

BIOCON GENERICS's Key Drugs

BIOCON GENERICS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BIOCON GENERICS's Recent FDA Approvals

New NDA/BLA approvals for BIOCON GENERICS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BIOCON GENERICS's Therapeutic Areas

BIOCON GENERICS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%
1 drugs

BIOCON GENERICS's Top Competitors

BIOCON GENERICS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Cardiovascular
Merck big-pharma
Cardiovascular
Baxter specialty
Cardiovascular
Sanofi big-pharma
Cardiovascular
Bayer big-pharma
Cardiovascular

BIOCON GENERICS Pipeline Snapshot

Active clinical trials for BIOCON GENERICS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 7 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges